# Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

> **NCT06005818** · PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 100 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab injection

## Key facts

- **NCT ID:** NCT06005818
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2027-07
- **Final completion:** 2028-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06005818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06005818, "Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06005818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*